Creatine for multiple sclerosis: what the trials show

Creatine has not been shown to help people with multiple sclerosis (MS). The two controlled trials, both small and short, found that it did not improve muscle work, and in one it did not even raise creatine levels in muscle. Interest has not gone away, because brain scans in MS show changes in creatine metabolism, but that idea has not been tested in a proper trial. If you have MS and are thinking about creatine, treat it as unproven and talk to your neurologist first.

Evidence grade

QuestionGradeWhy
Creatine improves muscle strength or work capacity in MSNot shownTwo small RCTs (16 and 11 people) found no benefit
Creatine reduces MS fatigueNot shownOne small crossover RCT found no change in habitual fatigue
Creatine slows MS progressionNo dataNo trial has tested it
Creatine slows other neurological diseasesNot shownLarge RCTs in Parkinson's and Huntington's disease and a Cochrane review in ALS found no benefit
Creatine is safeModerateWell tolerated in long trials in other conditions; MS trials too small to judge

Key takeaways

Why people ask about creatine and MS

MS damages the insulation around nerves in the brain and spinal cord. Muscle weakness and fatigue are common in MS, and creatine is one of the best studied supplements for muscle energy. In healthy people who train, it helps muscles do slightly more work in short, hard efforts. The question is whether that carries over to muscles that are weak because their nerve supply is damaged.

There is a second reason. Brain scans using magnetic resonance spectroscopy can measure creatine in brain tissue, and a 2022 review by Sergej Ostojic summarized human studies showing altered creatine levels in the brain and other tissues in MS. He suggests that a creatine deficit in the brain could be a feature of severe MS and a possible target for treatment.

The two trials

TrialWhoDose and designResult
Lambert 2003, Arch Phys Med Rehabil16 people with relapsing remitting MS (median disability score 4.75)20 g a day for 5 days or placebo; 8 per group; double blindNo significant rise in muscle total creatine, phosphocreatine or free creatine; no improvement in total work over 3 bouts of 30 maximal knee extensions and flexions
Malin 2008, J Diet Suppl11 people with MSCrossover: 20 g a day (four 5 g doses) for 7 days, then 5 g a day (two 2.5 g doses) for 7 days, or placebo, with a 3 week washoutNo improvement in knee extension or flexion work or power; no improvement in habitual fatigue

Both trials were small and short, and both measured muscle performance rather than disability, relapses or brain outcomes. The Lambert finding is notable because in healthy men, 20 g a day for 6 days raised muscle total creatine by about a fifth (Hultman 1996). Why it did not here is unclear, and the trial was too small to say whether that reflects MS itself or chance.

What creatine has done in other brain diseases

Creatine has been tested much more seriously in other neurological diseases, and the results have been disappointing:

None of these were MS trials, so they do not settle the MS question. They do show that promising lab and imaging findings for creatine in brain disease have so far not turned into clinical benefit.

For creatine's effects on the healthy brain, see our page on creatine dose for brain and memory. For a related injury setting, see creatine for traumatic brain injury.

What other MS supplement research says

A 2018 review in JAMA Neurology (Evans, Piccio and Cross) looked at vitamins and supplements used by people with MS. It concluded that vitamin D was the only vitamin with enough evidence to support routine supplementation in MS, that most supplement trials in MS were small or not blinded, and that vitamin deficiencies should be avoided. It also said doctors should know which supplements their patients take and tell them about possible medication interactions and side effects.

If you are considering it

This page is general information, not medical advice.

Get the free Longevity Supplement Starter Guide

Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.

Sources

1. Lambert CP, Archer RL, Carrithers JA, Fink WJ, Evans WJ, Trappe TA. Influence of creatine monohydrate ingestion on muscle metabolites and intense exercise capacity in individuals with multiple sclerosis. Arch Phys Med Rehabil. 2003;84(8):1206-1210. PMID 12917861

2. Malin SK, Cotugna N, Fang CS. Effect of creatine supplementation on muscle capacity in individuals with multiple sclerosis. J Diet Suppl. 2008;5(1):20-32. PMID 22433042

3. Ostojic SM. Creatine and multiple sclerosis. Nutr Neurosci. 2022;25(5):912-919. PMID 32912105

4. Ostojic SM, Ostojic J, Zanini D, Jezdimirovic T, Stajer V. Guanidinoacetate-creatine in secondary progressive multiple sclerosis: a case report. J Int Med Res. 2022;50(1):3000605211073305. PMID 35000485

5. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators; Kieburtz K, Tilley BC, Elm JJ, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015;313(6):584-593. PMID 25668262

6. Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R, et al. The CREST-E study of creatine for Huntington disease: a randomized controlled trial. Neurology. 2017;89(6):594-601. PMID 28701493

7. Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;12(12):CD005225. PMID 23235621

8. Evans E, Piccio L, Cross AH. Use of vitamins and dietary supplements by patients with multiple sclerosis: a review. JAMA Neurol. 2018;75(8):1013-1021. PMID 29710293

9. Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017;14:18. PMID 28615996

10. Hultman E, Söderlund K, Timmons JA, Cederblad G, Greenhaff PL. Muscle creatine loading in men. J Appl Physiol (1985). 1996;81(1):232-237. PMID 8828669